Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating Loxo’s larotrectinib in treating TRK cancers with upcoming data in Q4

Ticker(s): LOXO, EXEL, RXDX, NVS

Who's the expert?

An oncologist with clinical experience in treating TRK fusion cancers with at least one of the available multikinase/TRK inhibitors.

Interview Questions
Q1.

Please describe your clinical experience and the patient demographics who suffer from TRK fusion cancers.

Added By: c_admin
Q2.

Out of all the 55 patients enrolled in LOXO’s 101 trials, 22% had either stagnated or progression in the disease, and in 76% of the patients tumor reduction in size was observed. 12% of the patients had complete response rate. 6 patients responded to larotrectinib but subsequently progressed. What's your opinion of this data and how likely would you be to make a switch from other treatment options?

Added By: c_admin
Q3.

Have you used Cabozantinib (Cabometyx) in your clinical practice, since its FDA approval in April 2016?  What is the first line of treatment, when you need to use a TRK inhibitor drug? Have you been using midostaurin, crizotinib, entrectinib or regorafenib, and what has been your experience with them?

Added By: c_admin
Q4.

The FDA’s Pediatric Subcommittee granted its support for larotrectinib after observing its effects in a phase I trial enrolling patients 1 to 21 years of age. Are there bigger safety concerns regarding risk and adverse effects in this patient population?

Added By: c_admin
Q5.

On a scale from 1-10, with 10 being very excited, how would you rate your level of excitement for this drug if approved?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.